Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Positive topline clinical data for investigational topical presbyopia treatment
➤ FDA grants IDE for modular IOL with fluid-filled optic
➤ First participants enrolled in Phase 3 trial for mydriasis reversal
➤ Analysis: Subgroup of dry eye patients benefit from investigational treatment
➤ NDA approved for generic drug designed to treat inflammation, pain
➤ First patient enrolled in Phase 2a study for wet AMD and DME candidate
➤ ASCRS news and events
➤ New 5-year data with MIGS device
➤ Phase 2 results with new epi-on crosslinking technology
➤ FDA grants IDE, authorizes trial of new viscodilation system
➤ Robotic surgery for glaucoma
➤ First patient dosed in Phase 3 trial of investigational drop for DME
➤ New glaucoma device approved in European market, plus Phase 2 results
➤ ASCRS news and events
➤ Enrollment begins in Phase 3 pilocarpine study for presbyopia
➤ New digital platform enhances connectivity among clinic-to-OR technologies
➤ Positive results from Phase 1 safety study of investigational compound for AMD, DME
➤ Alcon to acquire Ivantis
➤ ASCRS news and events
➤ FDA approves first prescription eye drop for presbyopia treatment
➤ Primary endpoint reached in Phase 2 trial for dry eye disease drug
➤ New type of retinal nerve cell discovered
➤ Companies enter collaboration to develop an oral DME, wet AMD treatment
➤ iCare USA acquires remote patient-monitoring tech company
➤ ASCRS news and events
➤ FDA approves suprachoroidal injection for macular edema associated with uveitis
➤ FDA approves first-of-its-kind approach to treat wet AMD
➤ Digital therapeutic for pediatric amblyopia receives FDA premarket approval
➤ Ocular insert for dry eye does not meet Phase 2 primary endpoint
➤ Study: Prozac as a possible treatment for AMD
➤ ASCRS news and events
➤ FDA approves nasal spray for dry eye
➤ Survey: 70% of adults don’t plan on receiving an eye exam this year
➤ Positive results in Phase 3 study for Acanthamoeba keratitis treatment
➤ Research on first-in-class therapy for retinal degenerative disease
➤ ASCRS news and events
➤ Phase 3 clinical trial results for once-daily netarsudil ophthalmic solution
➤ Dexamethasone ophthalmic insert approved for new indication
➤ Results from home OCT feasibility study
➤ FDA accepts application for brolucizumab for DME
➤ Companies form alliance to develop nomograms, lens constants and astigmatism calculations
➤ AAO announces next CEO
➤ ASCRS news and events
➤ Positive topline results from Phase 3 trial for first-in-class dry eye drop
➤ Study: Long-term efficacy of neuromyelitis optica spectrum disorder treatment
➤ Long-term data from gene therapy injection for wet AMD
➤ Positive data from Phase 1/2 trial of gene therapy for geographic atrophy
➤ Ophthalmic device company partners with augmented reality tech company
➤ Survey: Patient perspectives on presbyopia
➤ Study: Wearable visual field testing device correlates with standard testing, offers efficiency
➤ Endpoints not met in blepharitis drug trial
➤ Retinal cell protection observed in non-clinical model with investigational IOP-lowering drug
➤ Extension study of investigational wet AMD therapy shows reduction of injection burden
➤ 12-month safety data reported from Phase 3 bevacizumab trial
➤ ASCRS news and events
➤ New and updated products for cataract workflow announced
➤ FDA approves first biosimilar in ophthalmology
➤ Acquisition of gene therapy company
➤ Licensing agreement for compounds targeting Demodex mites
➤ ASCRS news and events
